PRO-169

Asset

Stage
Phase 3
Modality
Antibody
Target
Not known
1
Indication
2,013
Trials
1
Developer

Trial NCT05217680 completed on Nov 25, 2025. clinicaltrials.gov

Indications

1

In the full profile

  • Target and mechanism1
  • Owner and partners1
  • Trials2,013
  • Evidence for its targets1
  • Competitors12
  • Signals13

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets